OS Therapies acquires Ayala's listeria IP for $8M, eliminates milestones, adds Phase 2 lung asset

OS Therapies Inc

Total consideration $8M: $0.5M cash + $7.5M in OSTX shares; 180-day lock-up. Closes ~60 days.
Eliminates $3.5M BLA milestone and $16.5M in OST-HER2 sales milestones; royalty reduced from 10% to 1.5% under Penn License.
Adds Phase 2 ADXS-503 (NSCLC) and Phase 1 ADXS-504 (prostate) programs using Listeria monocytogenes platform.
Karim Galzahr appointed to board; managing partner at OKG Capital, over 30 yrs finance experience.
Company has $7.1M financing at $4/share; cash runway into 2026; no equity raises below $12 for 6 months.

item 1.01 item 3.02 item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Karim Galzahr

Director

OSTX · OS Therapies Inc

Effective: 2025-01-28
Filed: January 29, 2025, 6:59 PM ET

On January 28, 2025, Karim Galzahr was elected to the Company’s board of directors.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Karim Galzahr was elected as Director at OS Therapies Inc.

Action: elected
Role: Director

Exact text from the filing

On January 28, 2025, Karim Galzahr was elected to the Company’s board of directors.

View on SEC.gov

OS Therapies Inc filing history →

Source: SEC EDGAR

accession 0001213900-25-007705

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.